GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lexagene Holdings Inc (OTCPK:LXXGQ) » Definitions » Earnings per Share (Diluted)

Lexagene Holdings (Lexagene Holdings) Earnings per Share (Diluted) : $-0.07 (TTM As of Nov. 2022)


View and export this data going back to 2017. Start your Free Trial

What is Lexagene Holdings Earnings per Share (Diluted)?

Lexagene Holdings's Earnings per Share (Diluted) for the three months ended in Nov. 2022 was $-0.01. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Nov. 2022 was $-0.07.

Lexagene Holdings's EPS (Basic) for the three months ended in Nov. 2022 was $-0.01. Its EPS (Basic) for the trailing twelve months (TTM) ended in Nov. 2022 was $-0.07.

Lexagene Holdings's EPS without NRI for the three months ended in Nov. 2022 was $-0.01. Its EPS without NRI for the trailing twelve months (TTM) ended in Nov. 2022 was $-0.07.


Lexagene Holdings Earnings per Share (Diluted) Historical Data

The historical data trend for Lexagene Holdings's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lexagene Holdings Earnings per Share (Diluted) Chart

Lexagene Holdings Annual Data
Trend Mar13 Mar14 Mar15 Feb16 Feb17 Feb18 Feb19 Feb20 Feb21 Feb22
Earnings per Share (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.08 -0.13 -0.10 -0.10 -0.09

Lexagene Holdings Quarterly Data
Feb18 May18 Aug18 Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.02 -0.02 -0.02 -0.02 -0.01

Competitive Comparison of Lexagene Holdings's Earnings per Share (Diluted)

For the Medical Devices subindustry, Lexagene Holdings's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lexagene Holdings's PE Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Lexagene Holdings's PE Ratio distribution charts can be found below:

* The bar in red indicates where Lexagene Holdings's PE Ratio falls into.



Lexagene Holdings Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Lexagene Holdings's Earnings Per Share (Diluted) for the fiscal year that ended in Feb. 2022 is calculated as

Diluted Earnings Per Share (A: Feb. 2022 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-10.62-0)/119.976
=-0.09

Lexagene Holdings's Earnings Per Share (Diluted) for the quarter that ended in Nov. 2022 is calculated as

Diluted Earnings Per Share (Q: Nov. 2022 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-1.678-0)/139.009
=-0.01

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Nov. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Lexagene Holdings  (OTCPK:LXXGQ) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Lexagene Holdings Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Lexagene Holdings's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Lexagene Holdings (Lexagene Holdings) Business Description

Traded in Other Exchanges
N/A
Address
500 Cummings Center, Suite 4550, Beverly, MA, USA, 01915
Lexagene Holdings Inc is a molecular diagnostics company that develops molecular diagnostic systems for pathogen detection and genetic testing for other molecular markers for on-site rapid testing in veterinary diagnostics, and for use in open-access markets such as food and water safety, clinical research, agricultural testing and biodefense. The MiQLab system delivers sensitivity, specificity, and breadth of detection and can return results in approximately two hours. The unique open-access feature is designed for custom testing so that end-users can load their own real-time PCR assays onto the instrument to target any genetic target of interest.